- Home
- ALEC vs CHRS Comparison
ALEC vs CHRS Comparison
Compare ALEC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | CHRS |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | 144 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 185.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ALEC | CHRS |
|---|---|---|
| Price | $2.03 | $1.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.83 | ★ $5.51 |
| AVG Volume (30 Days) | ★ 1.0M | 781.6K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,045,000.00 | N/A |
| Revenue This Year | $2.03 | $73.08 |
| Revenue Next Year | $29.87 | $30.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.09 | $1.03 |
| 52 Week High | $3.40 | $2.62 |
Technical Indicators
Market Signals| Indicator | ALEC | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 32.53 |
| Support Level | $1.93 | $1.15 |
| Resistance Level | $2.10 | $1.46 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 81.94 | 12.66 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.